Results 191 to 200 of about 93,087 (311)

Clinical Outcomes of Allogeneic Stem Cell Transplantation in Myelofibrosis - A Single Center Experience. [PDF]

Blood Cell Ther
Joshi N, Kulkarni U, Selvarajan S, Lionel S, Korula A, Na F, Lakshmi KM, Maddali M, Sindhuvi E, Balasubramanian P, Abraham A, Mathews V, George B.   +12 more
europepmc   +1 more source

Clinical Impact of Maximum Plasma Concentration of Busulfan in Pediatric Patients Undergoing Allogenic Hematopoietic Stem Cell Transplantation

Clinical Pharmacology &Therapeutics, EarlyView.
Busulfan's narrow therapeutic index and high pharmacokinetic (PK) variability warrant investigation of its exposure–toxicity relationship. We retrospectively analyzed 334 pediatric and young adult patients who underwent allogeneic hematopoietic stem cell transplantation at Seoul National University Children's Hospital between 2009 and 2020 and received
Sungyeun Bae, Jung Yoon Choi, Kyung Taek Hong, Bo Kyung Kim, Hyun Jin Park, Kyung‐Sang Yu, Su‐jin Rhee, Hyoung Jin Kang   +7 more
wiley   +1 more source

Successful allogeneic stem cell transplantation for a patient with high titers of donor-specific antibody after multiple desensitization procedures. [PDF]

Blood Cell Ther
Izumi K, Yoshioka K, Ueda Y, Kakihara B, Nakao K, Kitagawa T, Nagai K, Io K.   +7 more
europepmc   +1 more source

Allogeneic peripheral blood stem cell transplantation [PDF]

Immunohematology, 1999
J C, Whitehead, C D, Hillyer
openaire   +2 more sources

Ruxolitinib Pharmacokinetics and Exposure–Toxicity Relationship in Hematologic Malignancies and Immune‐Mediated Diseases: A Prospective Observational Study

Clinical Pharmacology &Therapeutics, EarlyView.
Ruxolitinib pharmacokinetics (PK) has been characterized in clinical trials but remains poorly documented in real‐world practice. This project aimed to investigate ruxolitinib PK in routine clinical practice, identify factors driving its variability, and explore exposure–response relationships to assess the potential role of therapeutic drug monitoring.
Jérémie Tachet, Sara C. Meyer, Francesco Grandoni, Emmanuel Haefliger, Monika Nagy‐Hulliger, Jörg P. Halter, Jakob R. Passweg, David Haefliger, Carine Bardinet, Laurent A. Decosterd, Monia Guidi, François R. Girardin   +11 more
wiley   +1 more source

Differential impact of allogeneic stem-cell transplantation on large B-cell lymphomas and peripheral T-cell lymphomas. [PDF]

Ann Hematol
Yoshino F, Kaji D, Kuno M, Watanabe O, Yamaguchi K, Kageyama K, Taya Y, Nishida A, Takagi S, Yamamoto H, Asano-Mori Y, Wake A, Taniguchi S, Uchida N, Yamamoto G.   +14 more
europepmc   +1 more source

Measurable residual disease by multicolor flow cytometry in acute myeloid leukemia: A comparison of peripheral blood and bone marrow

Cytometry Part B: Clinical Cytometry, EarlyView.
Abstract Measurable residual disease (MRD) monitoring by multiparameter flow cytometry (MFC) is well established in bone marrow (BM) samples for acute myeloid leukemia (AML), but its use in peripheral blood (PB) remains less developed. We adapted a semi‐automated and well validated MFC‐MRD assay, originally developed for BM, to PB aiming to evaluate ...
Jonas Schadt, Malte von Bonin, Uta Oelschlägel, Christoph Röllig, Christian Thiede, Leo Ruhnke, Martin Bornhäuser, Sebastian Brenner, Maximilian Alexander Röhnert   +8 more
wiley   +1 more source

αβT/CD19-depleted Allogeneic Stem Cell Transplantation in Adults with Inborn Errors of Immunity. [PDF]

J Clin Immunol
de Winter JJH, Ibrahimov BM, Verheij FA, Brinkman ID, Stuut AHG, Schonewille P, Heijstek MW, van Rhenen A, van der Wagen LE, Daenen LGM, Janssen A, Hutten TJA, Kuball J, Leavis HL, de Witte MA.   +14 more
europepmc   +1 more source

Establishment of pediatric reference ranges for circulating naïve and memory T and B cell subsets guided by the human immunophenotyping consortium standardization initiative: A large, single center U.S. experience

Cytometry Part B: Clinical Cytometry, EarlyView.
Abstract Our knowledge of the immune system continues to expand at a rapid pace, and this coupled with technological advances now enables us to interrogate both the breadth and the depth of the immune response at levels without precedent. This has also facilitated rapidly integrating some of this carefully vetted knowledge into clinical practice ...
Aaruni Khanolkar, Aisha Ahmed
wiley   +1 more source

Immune monitoring for relapse of acute myeloid leukemia after allogeneic stem cell transplantation in clinical laboratories. [PDF]

Front Immunol
Demir A, Aydın F, Yanıkkaya Demirel G.
europepmc   +1 more source